Erratum: Development of a manufacturing process for an HCV protease inhibitor candidate molecule (Organic Process Research and Development (2015) 19:1 (270?283) DOI: 10.1021/op500210w)

Full text of DOI:10.1021/acs.oprd.5b00005

Addition/Correction
pubs.acs.org/OPRD
Correction to “Development of a Manufacturing Process for an HCV
Protease Inhibitor Candidate Molecule”
Benjamin J. Littler,* Michael Aizenberg, Narendra B. Ambhaikar, Todd A. Blythe, Timothy T. Curran,
Vadims Dvornikovs, Young C. Jung, Valdas Jurkauskas, Elaine C. Lee, Adam R. Looker, Hoa Luong,
Theodore A. Martinot, David B. Miller, Bobbianna J. Neubert-Langille, Pieter A. Otten, Peter J. Rose,
and Piero L. Ruggiero
Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and
11010 Torreyana Road, San Diego, California 92121, United States
Org. Process Res. Dev. 2015, 19 (1), 270−283; 10.1021/op500210w
t has been brought to our attention that the structure for
Icompound 7 was incorrectly drawn in Schemes 6 and 7 of our
recently published manuscript “Development of a Manufacturing
Process for an HCV Protease Inhibitor Candidate Molecule”
(DOI: 10.1021/op500210w) as shown below in Figure 1.
Figure 1. Correction required to the structure of compound 7 in
Schemes 6 and 7.
The corrected versions of Schemes 6 and 7 are shown here.
Scheme 6. Initial approach to isolate spirocycle 2 as a single diastereomer (corrected)
© XXXX American Chemical Society
A
DOI: 10.1021/acs.oprd.5b00005
Org. Process Res. Dev. XXXX, XXX, XXX−XXX

Organic Process Research & Development
Addition/Correction
Scheme 7. Pilot-plant synthesis of spirocycle 2·HCl
(corrected)
AUTHOR INFORMATION
Corresponding Author
*E-mail: benjamin_littler@vrtx.com.
■
B
DOI: 10.1021/acs.oprd.5b00005
Org. Process Res. Dev. XXXX, XXX, XXX−XXX